| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Nektar Therapeutics (NKTR) has 8 insiders with recent SEC Form 4 filings, including 0 buys and 11 sells. NKTR is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 75.9K | $4.99M | - | |
| Other | 21.6K | $1.42M | - | |
| Other | 15.4K | $1.01M | -5,538 | |
| Dir | 8.0K | $525.6K | - | |
| Dir | 8.0K | $525.6K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 19, 2025 | Wilson Mark Andrew58 | Chief Legal Officer | Sell | 676 | $26.59 | $17,974.84 | -3.2% | +123.0% | - | |
| Aug 19, 2025 | Robin Howard W58 | President &CEO | Sell | 1,573 | $26.59 | $41,826.07 | -2.2% | +123.0% | - | |
| May 19, 2025 | Zalevsky Jonathan63 | Chief R&D Officer | Sell | 10,712 | $0.67 | $7,177.04 | -3.4% | +163.1% | +548.2% | |
| May 19, 2025 | Wilson Mark Andrew58 | Chief Legal Officer | Sell | 9,996 | $0.67 | $6,697.32 | -3.1% | +163.1% | +548.2% | |
| May 19, 2025 | Robin Howard W58 | President &CEO | Sell | 23,208 | $0.67 | $15,549.36 | -2.1% | +163.1% | +548.2% | |
| Feb 19, 2025 | Wilson Mark Andrew58 | Chief Legal Officer | Sell | 11,040 | $1.01 | $11,150.40 | -3.3% | -31.3% | +392.4% | |
| Feb 19, 2025 | Zalevsky Jonathan63 | Chief R&D Officer | Sell | 10,300 | $1.01 | $10,403.00 | -3.2% | -31.3% | +392.4% | |
| Feb 19, 2025 | Robin Howard W58 | President &CEO | Sell | 23,774 | $1.01 | $24,011.74 | -2.1% | -31.3% | +392.4% | |
| Dec 24, 2024 | Wilson Mark Andrew58 | Chief Legal Officer | Sell | 49,962 | $0.90 | $44,800.20 | -6.8% | -5.2% | +222.7% | |
| Dec 19, 2024 | Zalevsky Jonathan63 | Chief R&D Officer | Sell | 51,115 | $0.94 | $48,048.10 | -13.5% | -4.7% | +231.8% |